Semaglutide, Tirzepatide and Retatrutide: receptor profiles
The three compounds form a series from one receptor to three. The table shows the structural difference that receptor research works with.
| Compound | Receptors |
|---|---|
| Semaglutide | GLP-1 (single agonist), 31 amino acids |
| Tirzepatide | GLP-1 and GIP (dual agonist), 39 amino acids |
| Retatrutide | GLP-1, GIP and glucagon (triple agonist) |
Buy GLP-1 research peptides: vial sizes
Semaglutide comes in 2, 5, 10 and 15 mg, Tirzepatide in 5, 10, 15 and 30 mg, Retatrutide in 5, 10 and 15 mg. Small vials suit single receptor assays and method tests, large vials suit series from one lot. Every vial carries the amount and the lot number on the label. For Tirzepatide and Retatrutide a certificate of analysis is on file for documented batches, reported by mass spectrometry and HPLC.
What the incretin peptides are studied for
All three are used in receptor pharmacology: binding and activation assays, signalling studies and comparison of single, dual and triple agonists in cell models. A second field is analytics, because the modified sequences and the fatty diacid side chains make these peptides useful reference compounds for HPLC and mass spectrometry method development. Our guide Retatrutide: what the research shows summarises the published work on the triple agonist. These are research fields, not statements about effects in humans.
Research chemicals, not medicines
Medicines with the active substances Semaglutide and Tirzepatide exist. The products in this collection are not those medicines. They are research chemicals for laboratory use, without marketing authorisation, and we give no information on use in humans. The complete range is listed under all research peptides.
All compounds on this page are research chemicals for laboratory use only. They are not medicines, supplements, foods or cosmetics and are not intended for human or veterinary use.